Sell Your Science - Best Practices for Developing an Effective Non-Confidential Pitch Deck

Add this event to your calendar:
26/04/2016 13:30 26/04/2016 15:00 America/Toronto Sell Your Science - Best Practices for Developing an Effective Non-Confidential Pitch Deck MaRS Discovery District , CR-3 , Toronto , ON M5G 1L7 JLABS @ Toronto false DD/MM/YYYY
April
26
Event

Sell Your Science - Best Practices for Developing an Effective Non-Confidential Pitch Deck

MaRS Discovery District , CR-3 , Toronto , ON M5G 1L7

April 26, 2016 from 13:30 PM to 15:00 PM (EDT)

$10 - $35


It can be tricky to communicate the full potential of your discoveries without spilling the secret sauce. Join us every other week for sessions on learning the tricks of the trade in preparing a non-confidential deck and executive summary. Experts of the craft will share practical tips on becoming more effective in communicating your story to Angel investors and VCs, increasing your chances of successful fundraising.

Agenda:
11:30 AM | Registration, Networking and Lunch*
12:00 PM | Presentation
12:45 PM | Q&A
1:00 PM | Program Close

*Light food & beverage provided

Speakers:
Stefan Larson | CEO, Northern Biologics read bio»
Mary Haak-Frendscho | CEO, Blueline Bioscience read bio»

Who should attend:
This workshop is ideal for inventors in academic centers and hospitals, and early stage healthcare start-ups in the pharma, medical device, consumer health and digital innovation areas.

Fees:
There is no cost to attend this workshop, but pre-registration is required.

Location:
MaRS Discovery District
CR-3
101 College St.
Toronto, ON M5G 1L7

Speakers' Biographies:

Stefan Larson, Ph.D. | CEO, Northern Biologics
Stefan Larson is an Entrepreneur-in-Residence with Versant Ventures, and co-founded Northern Biologics in his role as President of Blueline Bioscience, a Toronto-based biotechnology incubator. Prior to joining Versant, Stefan was the co-founding CEO of Tornado Medical Systems, a revenue stage scientific and medical instruments company with product lines in high performance Raman spectroscopy and optical coherence tomography. He began his professional career as a management consultant with McKinsey & Company, serving clients in the healthcare and technology sectors as an Associate Principal in the firm. Stefan received his Ph.D. in Biophysics from Stanford University, where he studied as a James H. Clark Graduate Fellow. He received his MSc in Molecular and Medical Genetics from the University of Toronto.
Connect with Stefan: Connect on LinkedIn



Mary Haak-Frendscho, Ph.D. | CEO, Blueline Bioscience
Mary Haak-Frendscho, Ph.D. is CEO of Blueline Bioscience, a biotechnology incubator backed by Versant Ventures that identifies, develops and builds innovative biotechnology companies with world-leading scientists from across Canada. Dr. Haak-Frendscho also serves as Executive Chairman of Sirenas, a marine inspired therapeutics company in San Diego, and Board member of Northern Biologics, an emerging oncology therapeutics company in Toronto. Previously, she established and served as Chairman of Compugen, Inc., a subsidiary of Compugen, Ltd., translating in silico predicted targets into immuno-oncology therapeutics, and was CEO and member of the Board at Igenica Biotherapeutics, Inc., focused on the discovery and development of first-in-class antibody-based cancer therapeutics. Prior to that, Dr. Haak-Frendscho was founding President, Chief Scientific Officer and Board member of Takeda San Francisco, establishing and overseeing Takeda's Biologics Center of Excellence. Earlier in her career Dr. Haak-Frendscho held positions of increasing responsibility at XOMA, Abgenix (now Amgen), and Genentech, where she secured collaborative relationships with external corporate partners and led therapeutic antibody programs. At Genentech, she played a key role in the development of omalizumab (Xolair®). Dr. Haak-Frendscho has over 70 scientific articles and over 35 issued plus pending patents. An immunologist by training, Dr. Haak-Frendscho obtained her BS from the University of Michigan, MLA from Washington University in St. Louis, MS from SUNY-Stony Brook, CSEP from Columbia University Graduate School of Business and Ph.D. from the University of Wisconsin, where she has an adjunct appointment in the Department of Pathobiological Sciences.



JLABS @ Toronto

About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and healthtech sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to ten global locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto, Beerse (Belgium), with New York City, opening in June 2018, and Shanghai in 2019. For more information please visit www.jlabs.jnjinnovation.com or follow @JLABS.

Event contact


Related content